Monday, June 30, 2025 6/30/2025

Targeting RIP1-mediated pathways for immune homeostasis and tolerance

Award Number: R01AI119069
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/15/2016
PERIOD OF PERFORMANCE END DATE: 06/30/2023

Group Awards By:

View Award Description

Targeting RIP1-mediated pathways for immune homeostasis and tolerance - DESCRIPTION (provided by applicant): The focus of this project is to investigate RIPK1 (RIP or RIP1), a novel player in autoimmune diseases, as revealed in recent studies by us and others. We hypothesize that RIP1 could be a mediator in a variety of autoimmune conditions through activation of a pro-survival/proliferation signaling. Therefore, targeting RIP1 could serve as an effective therapeutic approach. Gene mutations in Fas (Apo-1 or CD95) could lead to an autoimmune-lymphoproliferative (lpr) syndrome (ALPS) with certain characteristics of lupus. RIP1 was originally identified as a potential Fas-interacting protein. Subsequent studies indicate that RIP1 is also a component of the signaling complex of tumor necrosis factor receptor 1 (TNFR1). As a result, Fas-/-TNFR1-/- double mutant mice develop accelerated lpr diseases. However, the physiological function of RIP1 is poorly understood due to perinatal lethality in RIP1-deficient mice. Using a novel conditional mutant animal model, our preliminary data indicates that RIP1 plays a critical role in T cells. In our previous study, RIP1 deficiency was able to rescue embryonic lethality in mice lacking FADD, a mediator of apoptosis induced by Fas or TNFR1 through recruiting and activating the initiator caspase 8. This discovery marks a turning point in our understanding of programmed cell death (PCD), by revealing a potent necroptosis (programmed necrosis) pathway mediated in vivo by RIP1. However, it remains unclear why RIP1-/- mice and RIP1-/- FADD-/- double mutant mice display perinatal lethality. In contrast, embryonic and postnatal development was normal in animals lacking both FADD and RIP3. The latter is a homologue of RIP1 and exclusively signals necroptosis. Therefore, absence of FADD unleashes necrosis, which is dependent on RIP1 and/or RIP3. The resulting RIP1-/-FADD-/- double mutant mice develop ALPS/lpr, which are more severe than that in Fas mutant mice. Here, we hypothesize that targeting RIP1 would promote cell death and serves as a strategy for treating lpr-autoimmune disease. However, the regulatory mechanism of this novel function of RIP1 in the immune system is not well understood. Therefore, we propose: 1) to test for the effect of genetic and pharmacological ablation of RIP1 function on suppressing lpr-autoimmune diseases; 2) to elucidate the pro-survival pathway(s) in primary lymphocytes that is mediated by RIP1; 3) to identify the structural/functional domain/motif in the RIP1 protein through in vivo functional complementation study, to facilitate drug design. Successful completion of these specific aims will provide new insights into the mechanisms regulated by RIP1 and lead to better design of therapies for lymphoproliferative, autoimmune and related diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$28,535 )
2024	2020	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	5	4/9/2024	NON-COMPETING CONTINUATION	-$28,535
														Subtotal = -$28,535

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	001	5	6/29/2022	NON-COMPETING CONTINUATION	$0
2022	2020	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	5	12/15/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $390,000 )
2020	2020	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	5	12/23/2019	NON-COMPETING CONTINUATION	$390,000
														Subtotal = $390,000

Issue Date FY: 2019 ( Subtotal = $390,000 )
2019	2019	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	4	12/19/2018	NON-COMPETING CONTINUATION	$390,000
														Subtotal = $390,000

Issue Date FY: 2018 ( Subtotal = $390,000 )
2018	2018	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	3	12/14/2017	NON-COMPETING CONTINUATION	$390,000
														Subtotal = $390,000

Issue Date FY: 2017 ( Subtotal = $390,000 )
2017	2017	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	2	12/12/2016	NON-COMPETING CONTINUATION	$390,000
														Subtotal = $390,000

Issue Date FY: 2016 ( Subtotal = $390,000 )
2016	2016	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	1	1/14/2016	NEW	$390,000
														Subtotal = $390,000

Grand Total All Awards = $1,921,465

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting RIP1-mediated pathways for immune homeostasis and tolerance

Award Number: R01AI119069

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/15/2016

PERIOD OF PERFORMANCE END DATE: 06/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer